Regeneron Pharmaceuticals, Inc.
REGN
announced first data from a descriptive analysis of a seamless phase I/II/III study, evaluating its antibody cocktail candidate, REGN-COV2, in non-hospitalized patients with COVID-19.
Data from the study showed that administration of REGN-COV2 plus usual standard-of-care (SoC) resulted in reduced viral load and the time to alleviate symptoms versus placebo plus SoC. The company stated that patients whose natural immune response was not yet adequate had the greatest treatment benefit, which suggests that REGN-COV2 holds potential as a therapeutic substitute for the naturally-occurring immune response.
Regeneron believes data from this cohort, which evaluated anti-viral activity of a one-time infusion of 8 grams of REGN-COV2 (high dose), 2.4 grams of REGN-COV2 (low dose) or placebo, and identified patients most likely to benefit from treatment, to be robust and encouraging. Currently, the study is ongoing and enrolment in the next cohort has been completed. This cohort could be used to rapidly and confirm the reported results.
The company has started discussing these results with regulatory authorities and may file regulatory applications seeking approval for REGN-COV2 as potential treatment for non-hospitalized COVID-19 patients following an outcome from its discussions.
Regeneron’s stock has surged 52.7% in the year so far compared with the
industry
’s rise of 2.2%.
The company is conducting a phase II/III study to evaluate REGN-COV2 for the treatment of COVID-19 in hospitalized patients. A phase III study is evaluating REGN-COV2’s ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient. The late-stage study is being run jointly with the National Institute of Allergy and Infectious Diseases (NIAID).
The candidate is also being evaluated in the phase III study — RECOVERY — sponsored by the University of Oxford. The study is evaluating the candidate in hospitalized patients for impact on hospital stay and the need for ventilation.
The company is one of the leading biotech companies along with Gilead Sciences, Inc.
GILD
working on drugs for the treatment of coronavirus. Another company developing an antibody treatment for COVID-19 is Vir Biotechnology
VIR
.
Meanwhile, Regeneron recently collaborated with Swiss pharma giant Roche
RHHBY
to develop, manufacture and distribute REGN-COV2, whereby the former will distribute REGN-COV2 in the United States. Regeneron’s efforts to develop REGN-COV2 are impressive and a positive outcome will be a great boost for the company and is much needed, given the widespread outbreak.
Regeneron Pharmaceuticals, Inc. Price
Regeneron Pharmaceuticals, Inc. price
|
Regeneron Pharmaceuticals, Inc. Quote
Zacks Rank
Regeneron currently carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it’s predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce “the world’s first trillionaires,” but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks’ 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
